Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 23, 2026
Subject: Announcement of headline results from the REDEFINE 4 open-label Phase 3 clinical trial for CagriSema (cagrilintide/semaglutide) in the treatment of obesity.
Key Financial Metrics
This filing is a clinical trial update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the outcome of the REDEFINE 4 trial, an 84-week study comparing CagriSema 2.4/2.4 mg to tirzepatide 15 mg in 809 participants with obesity.
- Primary Endpoint: Not achieved. CagriSema failed to demonstrate non-inferiority in weight loss compared to tirzepatide.
- Weight Loss Results (Treatment-Regimen Estimand):
- CagriSema: 20.2% weight loss.
- Tirzepatide: 23.6% weight loss.
- Weight Loss Results (Efficacy Estimand - Full Adherence):
- CagriSema: 23.0% weight loss.
- Tirzepatide: 25.5% weight loss.
- Safety Profile: CagriSema was safe and well-tolerated. Most common adverse events were gastrointestinal, mild to moderate, and diminished over time.
Guidance, Outlook, and Management Commentary
Management Commentary: Executive Vice President Martin Holst Lange stated that while the primary endpoint was not met, the 23% weight loss (under full adherence) is pleasing. He emphasized CagriSema's potential as the first GLP-1/amylin-combination product and noted that cagrilintide adds clinically meaningful benefits to semaglutide.
Regulatory and Development Outlook:
- US FDA Submission: Submitted in December 2025 based on REDEFINE 1 and 2 trials; decision anticipated by late 2026.
- REDEFINE 11: Phase 3 trial exploring full weight-loss potential; data expected in the first half of 2027.
- High-Dose Trial: Phase 3 trial for CagriSema 2.4 mg/7.2 mg planned for initiation in the second half of 2026.
Key Facts for Investor Verification
- Verify the impact of the missed primary endpoint in REDEFINE 4 on the anticipated FDA decision for CagriSema in late 2026.
- Monitor the upcoming REDEFINE 11 data readout (H1 2027) and the initiation of the higher-dose trial (H2 2026) to assess the full potential of the drug.
- Review the competitive landscape regarding tirzepatide, which demonstrated superior weight loss in this head-to-head comparison.
- Confirm the safety profile consistency with the GLP-1 class as reported in the trial.